罗氏速福达®正式在华获批扩龄至1岁及以上 守护儿童流感健康

Core Insights - Roche's antiviral treatment for influenza, Marbofloxacin, has received approval in China for expanded indications, allowing treatment for children aged 1 to 5 years with uncomplicated influenza, thus broadening its age coverage from previously 5 years and above [2][3] Group 1: Product Approval and Indications - Marbofloxacin oral suspension has been approved for children aged 1 to 5 years, including those at high risk for complications [2] - The tablet form of Marbofloxacin has been approved for adults and children aged 5 years and above, also including those at high risk for complications [2] - The new approvals provide a comprehensive treatment option for infants, children, and adults, enhancing the influenza prevention and control system in China [2] Group 2: Clinical Significance and Research - Influenza poses a significant public health threat, with seasonal influenza causing 3 to 5 million severe cases and 290,000 to 650,000 deaths globally each year [4] - Children are particularly vulnerable, with an annual infection rate of approximately 20%-30%, which can rise to 50% during peak seasons [4] - The new indications are based on two clinical studies conducted in children aged 1 to under 12 years, demonstrating the efficacy of Marbofloxacin compared to other treatments [5] Group 3: Expert Opinions - Experts emphasize the need for innovative treatments for young children, who are at high risk for severe complications from influenza [5] - The new formulations address challenges such as difficulty in swallowing and dosing accuracy for young patients [5] - The approval of Marbofloxacin for younger age groups is seen as a significant advancement in pediatric influenza treatment [5] Group 4: Company Statements and Future Directions - Roche's leadership highlights the ongoing public health challenge posed by influenza and the urgent need for innovative treatment options for high-risk children [6] - The company aims to enhance the accessibility of innovative drugs and contribute to the improvement of public health in China [6] - Marbofloxacin has shown effectiveness against various strains of influenza, including those resistant to other treatments, and is expected to significantly reduce the duration of symptoms [6][7]